Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment.
The complex syndrome of cancer cachexia (CC) that occurs in 50% to 80% cancer patients has been identified as an independent predictor of shorter survival and increased risk of treatment failure and toxicity, contributing to the mortality and morbidity in this population. CC is a pathological state including a symptom cluster of loss of muscle (skeletal and visceral) and fat, manifested in the cardinal feature of emaciation, weakness affecting functional status, impaired immune system, and metabolic dysfunction. The most prominent feature of CC is its non-responsiveness to traditional treatment approaches; randomized clinical trials with appetite stimulants, 5-HT3 antagonists, nutrient supplementation, and Cox-2 inhibitors all have failed to demonstrate success in reversing the metabolic abnormalities seen in CC. Interventions based on a clear understanding of the mechanism of CC, using validated markers relevant to the underlying metabolic abnormalities implicated in CC are much needed. Although the etiopathogenesis of CC is poorly understood, studies have proposed that NFkB is upregulated in CC, modulating immune and inflammatory responses induce the cellular breakdown of muscle, resulting in sarcopenia. Several recent laboratory studies have shown that n-3 fatty acid may attenuate protein degradation, potentially by preventing NFkB accumulation in the nucleus, preventing the degradation of muscle proteins. However, clinical trials to date have produced mixed results potentially attributed to timing of interventions (end stage) and utilizing outcome markers such as weight which is confounded by hydration, cytotoxic therapies, and serum cytokines. We propose that selective targeting of proteasome activity with a standardized dose of omega-3-acid ethyl esters, administered to cancer patients diagnosed with early stage CC, in addition to a standard intervention with nutritionally adequate diet and appetite stimulants, will alter metabolic abnormalities by downregulating NFkB, preventing the breakdown of myofibrillar proteins and resulting in increasing serum protein markers, lean body mass, and functional status.
Department of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA. nagi.kumar@moffitt.org
Nagi B
NB
Kumar
Aslam
A
Kazi
Tiffany
T
Smith
Theresa
T
Crocker
Daohai
D
Yu
Richard R
RR
Reich
Kiran
K
Reddy
Sally
S
Hastings
Martine
M
Exterman
Lodovico
L
Balducci
Kyle
K
Dalton
Gerold
G
Bepler
D002100:Cachexia / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D008519:Medicine, Traditional; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000150:complications / Q000628:therapy*